Department of Nephrology, First Affiliated Hospital of Anhui Medical University, Hefei, China.
Anhui Province Key Laboratory of Major Autoimmune Diseases, Anhui Institute of Innovative Drugs, School of Pharmacy, Anhui Medical University, Hefei, China.
Front Immunol. 2021 Oct 22;12:714026. doi: 10.3389/fimmu.2021.714026. eCollection 2021.
Previous studies indicated the calcium-binding protein S100A12 to be involved in the pathophysiology of pulmonary inflammatory diseases. However, the role of S100A12 has remained elusive in patients with community-acquired pneumonia (CAP). Therefore, the purpose of this prospective cohort study was to evaluate the association between serum S100A12 with severity and prognosis in CAP patients.
Two groups with either 239 CAP patients or 239 healthy controls were enrolled in our study. Fasting blood and clinical characteristics were collected. On admission, serum S100A12 was measured using enzyme-linked immunosorbent assay (ELISA).
Serum S100A12 was increased in CAP patients compared to control subjects. Furthermore, serum S100A12 was elevated according to the severity of CAP. Correlative analysis suggested that the level of serum S100A12 was associated with blood routine indices, renal function markers, inflammatory cytokines and other clinical parameters among CAP patients. Additionally, linear and logistical regression analyses indicated that serum S100A12 was positively associated with CAP severity scores in CAP patients. In addition, the association of high serum S100A12 and prognosis was accessed using a follow-up research. Elevated serum S100A12 on admission increased the risk of death and hospital stay in CAP patients during hospitalization.
Elevated serum S100A12 on admission is positively associated with the severity and adverse prognosis in CAP patients, suggesting that S100A12 may involve in the pathophysiological process of CAP. The titre of serum S100A12 may be used as a biomarker for diagnosis and prognosis among CAP patients.
先前的研究表明钙结合蛋白 S100A12 参与了肺部炎症性疾病的病理生理学过程。然而，S100A12 在社区获得性肺炎（CAP）患者中的作用仍不清楚。因此，本前瞻性队列研究的目的是评估血清 S100A12 与 CAP 患者严重程度和预后的相关性。
我们的研究纳入了两组患者，分别为 239 例 CAP 患者和 239 例健康对照者。采集空腹血和临床特征。入院时，采用酶联免疫吸附试验（ELISA）检测血清 S100A12。
与对照组相比，CAP 患者的血清 S100A12 升高。此外，血清 S100A12 随 CAP 的严重程度而升高。相关分析表明，CAP 患者的血清 S100A12 水平与血常规指标、肾功能标志物、炎症细胞因子和其他临床参数相关。此外，线性和逻辑回归分析表明，血清 S100A12 与 CAP 患者的 CAP 严重程度评分呈正相关。此外，通过随访研究评估了高血清 S100A12 与预后的关系。入院时升高的血清 S100A12 增加了 CAP 患者住院期间死亡和住院时间的风险。
入院时升高的血清 S100A12 与 CAP 患者的严重程度和不良预后呈正相关，提示 S100A12 可能参与 CAP 的病理生理过程。血清 S100A12 的浓度可能可作为 CAP 患者诊断和预后的生物标志物。
